EQS-News

TVM Capital Life Science Announces Creation of LAmAb Biologics to Develop Innovative Preventative Therapy for Allergy Patients

EQS-News: TVM Life Science Management GmbH / Key word(s): Investment TVM Capital Life Science Announces Creation of LAmAb Biologics to Develop Innovative Preventative Therapy for Allergy Patients 08.02.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. TVM Capital Life Science Announces Creation of LAmAb Biologics to Develop Innovative Preventative Therapy for Allergy Patients

LAmAb Biologics to develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases

LAmAb Biologics is the 9^th early-stage or product focused company (PFC) investment for TVM Life Science Innovation II Fund

Montreal, Canada / Munich, Germany – 08 February 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will invest up to USD 25 million in the newly formed U.S.-based biotechnology company, LAmAb Biologics (“LAmAb”), with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”). TVM will provide strategic advice to the company, with Dr. Sascha Berger, General Partner joining the Board of Directors and Marc Rivière, M.D., CMO, serving as a Board Observer. LAmAb is the 9^th early-stage or project-focused company (PFC) investment for TVM LS II.

LAmAb plans to develop a first-in-class monoclonal antibody (mAb) to clinical proof-of-concept in allergic rhinitis (hay fever), an indication that should enable LAmAb to efficiently show the program may be effective in humans. The antibody targets IgE, which is implicated in a broad set of allergy indications. The goal is to later expand development to other forms of IgE-mediated diseases such as asthma and food allergies, which annually affect over 30 million people in the U.S. alone.

"TVM Capital Life Science is proud to have enabled the creation of LAmAb Biologics and to have secured the rights to a novel first-in-class asset with the potential to positively impact challenging-to-treat allergic diseases. This investment is a testament to our strong international network and builds on our successful single asset focus for innovative preclinical therapeutic agents,” said Sascha Berger, General Partner of TVM Capital Life Science and Member of the Board of LAmAb Biologics. “We are pleased to collaborate with the well-proven management team of Caroline Fortier and Mark Cipriano, who will act as CEO and CFO, respectively, for LAmAb."